Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
If any single chart could tell the tale of Takeda’s global pharmaceutical ambitions, it would be one showing change in annual revenues. 27 October 2020
Generics
One of Russia’s largest plants for the production of active pharmaceutical ingredients (APIs) will soon be built in the St Petersburg region by the local enterprise Active Component JSC, a leading producer of pharmaceutical ingredients and drugs in the country, reports The Pharma Letter’s local correspondent. 26 October 2020
Pharmaceutical
Jonathan Roses, counsel Wolf, Greenfield & Sacks and Matthew Birkett, partner, Hoffmann Eitle, provide an Expert View on general treatment of salt and polymorphic forms in the US Patent and Trademark Office, the European Patent Office and the courts. 23 October 2020
Pharmaceutical
Reducing patient healthcare costs is imperative, write Matthew Majewski and Andrew Parece, vice presidents of Charles River Associates, in a Special Report. 21 October 2020
Pharmaceutical
The Russian government will increase the maximum selling prices for some vital and essential drugs available in the domestic market in order to prevent their shortage, reports The Pharma Letter’s local correspondent. 20 October 2020
Pharmaceutical
Another coronavirus quarter has come and gone, with pharma companies either thriving, doing their best to mitigate the negative impacts or somewhere in between. 19 October 2020
Generics
Pharma companies wishing bring their commercialized drugs to the Chinese market will now have to comply with new requirements by Chinese National Medical Products Administration (NMPA) when applying for a New Drug Application (NDA)/Abbreviated NDA approval in the country, reports The Pharma Letters local correspondent. 16 October 2020
Generics
India's Chemicals and Fertilizers Minister D V Sadananda Gowda has invited Latin American and Caribbean countries to invest in the Indian pharma sector, stating that it could grow to become a $65 billion industry by 2024. With the government recently launching schemes for the development of drug parks across the country, the Minister said India could well replace China as the world's factory, reports The Pharma Letter’s India correspondent. 16 October 2020
Generics
Russian generics producers have designed alternative ways for the launch of their products in the domestic market, bypassing the patents of Western drugmakers, reports The Pharma Letter’s local correspondent. 13 October 2020
Biotechnology
Despite the coronavirus pandemic causing chaos on a global scale throughout much of 2020, the US Food a d Drug Administration has strived to limit the impact on much-needed, novel drug approvals. 9 October 2020
Pharmaceutical
Japan remains on balance an attractive pharmaceutical market, with favorable volume dynamics, generally attractive pricing and broad and unfettered market access, writes Patrick Branch from LEK Consulting, in an Expert View piece. 7 October 2020
Pharmaceutical
The Russian pharmaceutical market is experiencing stagnation, despite the existing fears of the beginning of a second wave of the COVID-19 pandemic in the country, according to recent statements by some senior officials of the Russian Ministry of Health and local pharmaceutical analysts, reports The Pharma Letter’s local correspondent. 5 October 2020
Pharmaceutical
Rett syndrome (RTT) is a rare neurodevelopmental disorder, affecting about 1 in 10,000 girls born each year.1 Present at conception, RTT leads to major developmental regression around 6-30 months after birth, with patients typically becoming withdrawn and losing acquired social and motor skills. 5 October 2020
Biotechnology
The Russian government will revise plans for the purchase of some of the most expensive drugs for state needs this year due to the lack of funds in the state budget, according to some sources close to the federal government and local media, reports The Pharma Letter’s local correspondent. 29 September 2020
Generics
Earlier considered prohibitively expensive, treatments for multiple sclerosis (MS) have become affordable in India over the past few years, with doctors urging patients to come forward and receive treatment, instead of choosing to live with the disorder. With the government mulling several proposals to include MS along with 21 other disabilities in the Ayushman Bharat scheme, a National Health Protection Mission, MS patients can soon avail themselves of more benefits, reports The Pharma Letter’s India correspondent. 28 September 2020
Pharmaceutical
An Expert View from Karen Noonan at the Association of Clinical Research Organizations (ACRO) on adopting a more flexible approach to trials moving forward, something made all the more important by the COVID-19 pandemic. 28 September 2020
Pharmaceutical
Guyana’s pharmaceutical industry is important for the neighboring Caribbean, mainly as these small islands are usually overlooked by international pharma companies when it comes to doing business. 24 September 2020
Pharmaceutical
An Expert View from Jonathan Roses (pictured, left), counsel, Wolf, Greenfield & Sacks, and Matthew Birkett, partner, Hoffmann Eitle, on the granting of two patents for a single invention in the USA and Europe. 22 September 2020
Pharmaceutical
At the annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, Johnson & Johnson’s pharma arm Janssen hopes to raise the bar with quality of life data for Erleada (apalutamide). 17 September 2020
Pharmaceutical
Amid unprecedented demand, the supply of tocilizumab has dried up in India. As India's coronavirus cases surge past the five million mark on Wednesday after the Ministry of Health reported a single-day jump of 90,123 cases, the Central Drugs Standard Control Organization (CDSCO) has requested the Drug Controllers of all states to take immediate measures to prevent black marketing of remdesivir injections and has asked doctors not to prescribe tocilizumab randomly, reports The Pharma Letter’s India correspondent. 17 September 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze